Comparative Pharmacology
Head-to-head clinical analysis: DALGAN versus TALWIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALGAN versus TALWIN.
DALGAN vs TALWIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
Agonist at kappa-opioid receptors and antagonist at mu-opioid receptors; produces analgesia through spinal and supraspinal mechanisms.
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
50 mg orally every 3-4 hours as needed; maximum 600 mg/day. For severe pain, 30 mg intramuscularly or subcutaneously every 3-4 hours; maximum 360 mg/day parenterally.
None Documented
None Documented
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
2-3 hours in adults; prolonged to 4-6 hours in hepatic impairment; clinical context: short half-life necessitates frequent dosing for chronic pain
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Renal: 60-70% as unchanged drug and metabolites (pentazocine and its glucuronide conjugate); biliary/fecal: 20-30%
Category C
Category C
Opioid Analgesic
Opioid Analgesic